SPY422.11-2.37 -0.56%
DIA340.76-2.65 -0.77%
IXIC14,039.68-33.17 -0.24%

Keybanc Initiates Coverage On Recursion Pharmaceuticals with Overweight Rating, Announces Price Target of $36

Keybanc analyst Donald Hooker initiates coverage on Recursion Pharmaceuticals (NASDAQ:RXRX) with a Overweight rating and announces Price Target of $36.

05/11/2021 05:56
Keybanc analyst Donald Hooker initiates coverage on Recursion Pharmaceuticals (NASDAQ:RXRX) with a Overweight rating and announces Price Target of $36.